Login to Your Account



Ally Bridge gives Cold Genesys warm reception in $13.6M series A

By Marie Powers
Staff Writer

Friday, August 1, 2014
Health care investment firm Ally Bridge Group, which has offices in Hong Kong and the U.S., warmed up to Cold Genesys Inc., funding the cancer immunotherapy firm's $13.6 million series A. The Newport Beach, Calif., biotech has advanced its lead program, CG0070, into a phase II/III trial in patients with high-risk carcinoma in situ nonmuscle invasive bladder cancer (NMIBC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription